New study published by Medicover Genetics team demonstrates the value of our liquid biopsy test NeoThetis in clinical settings

Medicover Genetics Editorial Team|

Scientifically checkedView our editorial guidelines
Scientifically checked

Medicover Genetics is pleased to announce the successful publication of a collaborative research article in ESMO Gastrointestinal Oncology. The investigation evaluates the efficacy of anti-EGFR re-challenge strategies with the objective to improve precision treatment options for patients with metastatic colorectal cancer (CRC).

The research teams aimed to identify novel, clinically significant prognostic genetic biomarkers through translational molecular approaches. To facilitate the accurate identification of specific biomarkers, test, among other methods, has been utilised for the analysis. The findings highlight the reliability of NeoThetis in providing actionable insights on CRC development and therapy resistance mechanisms that could potentially improve CRC patients’ clinical management and outcomes.

“Our liquid biopsy test, NeoThetis for Therapy Selection, demonstrates utility and relevance in clinical settings as evident in this important study,” stated Dr. Marios Ioannidis Managing Director of Medicover Genetics, Cyprus. “This achievement resulted from the joint efforts of our R&D, Clinical Services, and esteemed external research collaborators. It underscores Medicover Genetics commitment to advancing research that yields new insights into disease mechanisms and identifies novel therapeutic avenues.”

Medicover Genetics is dedicated to delivering research excellence that directly benefits both healthcare providers and patients.

About NeoThetis liquid biopsy

NeoThetis is part of the NeoSentia liquid biopsy portfolio that identifies genetic alterations and genomic biomarkers in a patients’ tumour. It is specifically designed to maximize the available therapeutic opportunities which are based on precision medicine while guiding therapy selection and treatment re-evaluation tailored to each patient.

Last updated: June 8, 2026

Latest articles

All about genetics
Health and well-being
Hereditary diseases

  • VERACITY

    New-generation non-invasive prenatal screening from week 9 of pregnancy, analysing fetal cell-free DNA in maternal blood to detect selected chromosomal abnormalities with high sensitivity and specificity for early and reliable prenatal risk assessment.

  • Pharmacogenomics

    Enabling personalised treatments for safer, more effective care through genetic insights that guide optimal prescribing from the start and refine therapy when patients experience side effects or poor response.

  • ebiom+

    A comprehensive assessment of the endometrial microbiome and chronic endometritis pathogens to enhance clinical outcomes, prevent treatment delays, and support a more informed, personalised fertility care.

  • WES

    Advanced sequencing that simultaneously analyses a broad range of genes to detect the genetic basis of complex diseases, improve diagnostic accuracy, and inform recurrence risk assessment for better clinical decision-making.

Why Medicover Genetics

Leader in genetic testing with >25 years of experience in counselling and diagnostics

Comprehensive CE-IVD kit portfolio and seamless Technology Transfer solution for laboratories of any size

End-to-end clinical workflow from sample processing to sequencing analysis and reporting

CAP- and CLIA- and ISO15189 accredited, GMP- and ISO9001 and 13485 certified

Are you a patient?

Are you a physician?